Oxybutynin deemed effective treatment for hyperhidrosis

Oxybutynin deemed effective treatment for hyperhidrosis

(HealthDay)—Low-dose oxybutynin is an effective treatment for hyperhidrosis, according to a study published online June 26 in the British Journal of Dermatology.

Martine Schollhammer, M.D., from University Hospital in Brest, France, and colleagues examined the effectiveness and tolerance of low-dose oxybutynin for hyperhidrosis in a randomized placebo-controlled trial. Participants included 62 patients with localized or generalized hyperhidrosis (83 percent generalized). Oxybutynin was started at 2.5 mg per day and increased to 7.5 mg per day.

The researchers found that for improving the Hyperhidrosis Disease Severity Scale (HDSS), oxybutynin was superior to placebo, with improvement of at least one point on the HDSS for 60 percent of oxybutynin-treated patients versus 27 percent of placebo-treated patients. The mean improvement in quality of life, as measured by the Dermatology Life Quality Index, was significantly better for oxybutynin versus (6.9 versus 2.3). Dry mouth was the most frequent side effect, which was seen in 43 and 11 percent of those in the oxybutynin and placebo arms, respectively.

"Treatment with low-dose oxybutynin is effective in reducing symptoms of hyperhidrosis in generalized or localized forms," the authors write.

One author disclosed to Pfizer.

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: British Journal of Dermatology

Copyright © 2015 HealthDay. All rights reserved.

Citation: Oxybutynin deemed effective treatment for hyperhidrosis (2015, July 6) retrieved 29 November 2022 from https://medicalxpress.com/news/2015-07-oxybutynin-deemed-effective-treatment-hyperhidrosis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Larazotide acetate 0.5 mg found beneficial in celiac disease


Feedback to editors